AR083818A1 - Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico - Google Patents
Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilicoInfo
- Publication number
- AR083818A1 AR083818A1 ARP110104189A ARP110104189A AR083818A1 AR 083818 A1 AR083818 A1 AR 083818A1 AR P110104189 A ARP110104189 A AR P110104189A AR P110104189 A ARP110104189 A AR P110104189A AR 083818 A1 AR083818 A1 AR 083818A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- cycloalkyl
- unsubstituted
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente se refiere a un procedimiento para la preparación de un compuesto de la fórmula (1) y al compuesto de la fórmula (1).Reivindicación 1: Un procedimiento para obtener el compuesto de la fórmula (1) y/o todas las formas estereoisoméricas del compuesto de la fórmula (1) y/o mezclas de estas formas en cualquier proporción, donde A2 es aminopiridilo, en el que el aminopiridilo está sin sustituir o sustituido independientemente entre sí una, dos o tres veces con halógeno o metilo; Y es -cicloalquilo C3-8, en el que el cicloalquilo está sin sustituir o sustituido independientemente entre sí una, dos o tres veces con R1, donde R1 es a) fenilo, donde el fenilo está sin sustituir o sustituido una, dos o tres veces independientemente entre sí con -alquilo C1-4, b) halógeno, c) -alquilo C1-4-, d) -cicloalquilo C3-6-, e) -CF3, f) -O-CF3, g) triazolilo o h) piridinilo; R15 es un grupo protector de amino y Z es i) -alquilo C1-6, ii) -alquil C1-6-OH, iii) -alquileno C1-4-cicloalquilo C3-6, iv) -CH2-fenilo, donde el fenilo está sin sustituir o sustituido una o dos veces con NO2 o metoxi, v) -CH2-CH=CH2 o vi) -alquileno C1-10-O-C(O)-O-cicloalquilo C3-6, que comprende A) hacer reaccionar un compuesto de fórmula (2) con el compuesto de fórmula: R15-A2-CHO en la que R15 es un grupo protector de amino, para dar un compuesto de fórmula (1), o B) opcionalmente el compuesto de la fórmula (1) que se ha preparado por la etapa de proceso A) y que aparece, debido a su estructura química, en formas enantioméricas fraccionándose por formación de sal con ácidos o bases enantiopuras, cromatografía sobre fases estacionarias quirales o derivatización usando compuestos enantiopuros quirales tales como aminoácidos, separación de los diastereómeros obtenidos de esta manera, y eliminación de los grupos auxiliares quirales en los enantiómeros puros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10306246 | 2010-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083818A1 true AR083818A1 (es) | 2013-03-27 |
Family
ID=43901646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104189A AR083818A1 (es) | 2010-11-11 | 2011-11-09 | Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8940901B2 (es) |
| EP (1) | EP2638016B1 (es) |
| JP (1) | JP2013542235A (es) |
| KR (1) | KR20130130737A (es) |
| CN (1) | CN103201269A (es) |
| AR (1) | AR083818A1 (es) |
| AU (1) | AU2011328263A1 (es) |
| BR (1) | BR112013011244A2 (es) |
| CA (1) | CA2814911A1 (es) |
| IL (1) | IL225680A0 (es) |
| MX (1) | MX2013004193A (es) |
| RU (1) | RU2013126689A (es) |
| SG (1) | SG189420A1 (es) |
| WO (1) | WO2012062730A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145385B2 (en) * | 2011-11-25 | 2015-09-29 | Sanofi | Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid |
| EP2782576B1 (en) * | 2011-11-25 | 2016-05-18 | Sanofi | Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid |
| CN111349043B (zh) * | 2018-12-20 | 2022-09-27 | 上海医药工业研究院 | 用于制备派西尼布的中间体及其制备方法和应用 |
| CN111690699A (zh) * | 2020-05-19 | 2020-09-22 | 浙江工业大学 | 一种酶促在线合成3-（吡啶-2-氨基）丙羟肟酸的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0405602A1 (en) | 1989-06-30 | 1991-01-02 | Laboratorios Vinas S.A. | New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity |
| US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
| AU736026B2 (en) | 1997-12-17 | 2001-07-26 | Merck & Co., Inc. | Integrin receptor antagonists |
| DE69918799D1 (de) | 1998-01-14 | 2004-08-26 | Uab Res Foundation Birmingham | Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren |
| US6861448B2 (en) | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| WO2003061653A1 (en) | 2002-01-22 | 2003-07-31 | Pfizer Limited | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| US20030199523A1 (en) | 2002-02-28 | 2003-10-23 | Snutch Terrance P. | Heterocyclic calcium in channel blockers |
| JPWO2003091211A1 (ja) | 2002-03-28 | 2005-09-02 | 住友製薬株式会社 | 新規ヘテロアリール化合物 |
| US8710232B2 (en) | 2004-04-22 | 2014-04-29 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives used as TAFIa inhibitors |
| DE102004020186A1 (de) | 2004-04-22 | 2005-11-17 | Aventis Pharma Deutschland Gmbh | Heterocyclylessigsäuren als Inhibitoren von TAFla |
| CA2735184C (en) * | 2008-09-11 | 2013-05-28 | Pfizer Inc. | Heteroaryls amide derivatives and their use as glucokinase activators |
| AU2009310841A1 (en) * | 2008-10-29 | 2010-05-06 | Taisho Pharmaceutical Co., Ltd. | Compounds having TAFIa inhibitory activity |
| ES2431068T3 (es) * | 2009-05-15 | 2013-11-25 | Sanofi | Proceso para la preparación de un compuesto útil como un inhibidor de TAFIa |
| US8946443B2 (en) * | 2010-03-18 | 2015-02-03 | Daiichi Sankyo Company, Limited | Cyclopropanecarboxylic acid derivative |
-
2011
- 2011-11-08 SG SG2013028360A patent/SG189420A1/en unknown
- 2011-11-08 AU AU2011328263A patent/AU2011328263A1/en not_active Abandoned
- 2011-11-08 CA CA2814911A patent/CA2814911A1/en not_active Abandoned
- 2011-11-08 JP JP2013538156A patent/JP2013542235A/ja active Pending
- 2011-11-08 CN CN2011800536155A patent/CN103201269A/zh active Pending
- 2011-11-08 KR KR1020137014887A patent/KR20130130737A/ko not_active Withdrawn
- 2011-11-08 WO PCT/EP2011/069603 patent/WO2012062730A1/en not_active Ceased
- 2011-11-08 BR BR112013011244A patent/BR112013011244A2/pt not_active IP Right Cessation
- 2011-11-08 EP EP11779661.5A patent/EP2638016B1/en active Active
- 2011-11-08 MX MX2013004193A patent/MX2013004193A/es not_active Application Discontinuation
- 2011-11-08 RU RU2013126689/04A patent/RU2013126689A/ru not_active Application Discontinuation
- 2011-11-09 AR ARP110104189A patent/AR083818A1/es not_active Application Discontinuation
-
2013
- 2013-04-10 IL IL225680A patent/IL225680A0/en unknown
- 2013-05-08 US US13/889,761 patent/US8940901B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2814911A1 (en) | 2012-05-18 |
| SG189420A1 (en) | 2013-05-31 |
| EP2638016A1 (en) | 2013-09-18 |
| KR20130130737A (ko) | 2013-12-02 |
| IL225680A0 (en) | 2013-06-27 |
| JP2013542235A (ja) | 2013-11-21 |
| WO2012062730A1 (en) | 2012-05-18 |
| EP2638016B1 (en) | 2014-10-01 |
| US20130245274A1 (en) | 2013-09-19 |
| US8940901B2 (en) | 2015-01-27 |
| AU2011328263A1 (en) | 2013-05-30 |
| RU2013126689A (ru) | 2014-12-20 |
| BR112013011244A2 (pt) | 2017-10-24 |
| CN103201269A (zh) | 2013-07-10 |
| MX2013004193A (es) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| AR107010A1 (es) | Derivados de piperidina puenteados | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| CR20220157A (es) | Procedimiento para preparar (4s)–4–(4–ciano–2–metoxi–fenil)–5–etoxi–2,8–dimetil–1,4–dihidro–1,6–naftiridin–3–carboxilato de 2–cianoetilo mediante separación de racematos utilizando ésteres diastereoméricos de ácido tartárico | |
| IN2014MN01521A (es) | ||
| AR061761A1 (es) | Moduladores tiazolopirimidina de trpv1 | |
| AR105965A1 (es) | Derivados de piperidina puenteados | |
| RU2015145784A (ru) | Способ получения циклоалкилкарбоксамидо-индольных соединений | |
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| AR083818A1 (es) | Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| ES2721662T3 (es) | Proceso para la preparación de travoprost | |
| AR110122A1 (es) | Fenoxitriazoles | |
| EA201291376A1 (ru) | Новые кальциевые соли соединения в качестве противовоспалительных, иммуномодулирующих и антипролиферативных агентов | |
| UA108378C2 (uk) | Спосіб одержання плеуромутилінів | |
| AR094790A1 (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| RU2013141849A (ru) | Композиции и способы применения сложноэфирных производных биматопроста | |
| DK2285765T3 (da) | Fremgangsmåde til fremstilling af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| AR104331A1 (es) | Derivados de tetrazol | |
| WO2011142825A3 (en) | Novel sulfur containing compounds | |
| AR075394A1 (es) | Derivados del acido fenoxiacetico, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades inflamatorias,alergicas y neurodegenerativas. | |
| EA201590757A1 (ru) | Новые селективные модуляторы андрогенных рецепторов | |
| AR101222A1 (es) | Derivados de piridona | |
| CL2021000454A1 (es) | Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |